These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 9550589)

  • 1. The treatment of heart failure: the role of neurohumoral activation.
    Middlekauff HR; Mark AL
    Intern Med; 1998 Feb; 37(2):112-22. PubMed ID: 9550589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].
    MMW Fortschr Med; 2005 Jul; 147(27-28):45. PubMed ID: 16041943
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neurohumoral blocking agents].
    Kurisu S; Kihara Y
    Nihon Rinsho; 2011 Nov; 69 Suppl 9():394-6. PubMed ID: 22724235
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations.
    Francis GS
    J Cardiovasc Pharmacol; 1998; 32 Suppl 1():S16-21. PubMed ID: 9731691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neurohumoral mechanisms in cardiocirculatory decompensation].
    Grassi G; Mancia G
    Ann Ital Med Int; 1994 Oct; 9 Suppl():61S-67S. PubMed ID: 7857760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both?
    Anthonio RL; van Veldhuisen DJ; van Gilst WH
    J Cardiovasc Pharmacol; 1998; 32 Suppl 1():S1-8. PubMed ID: 9731689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
    Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
    Shinohara H; Fukuda N; Soeki T; Sakabe K; Onose Y; Tamura Y
    Heart Vessels; 2002 Dec; 17(2):47-52. PubMed ID: 12541093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and implications of autonomic nervous system dysfunction in heart failure.
    Middlekauff HR
    Curr Opin Cardiol; 1997 May; 12(3):265-75. PubMed ID: 9243084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What constitutes optimal neurohumoral antagonism in chronic heart failure?
    Tajik AA; Dickstein K
    Heart; 2016 Dec; 102(23):1922-1932. PubMed ID: 27742799
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neurohumoral regulation in heart failure].
    Riegger GA; Muders F; Luchner A
    Z Kardiol; 1996; 85 Suppl 6():205-10. PubMed ID: 9064967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial infarction, heart failure and sympathetic nervous system activity: new pharmacological approaches that affect neurohumoral activation.
    Ciarka A; van de Borne P; Pathak A
    Expert Opin Investig Drugs; 2008 Sep; 17(9):1315-30. PubMed ID: 18694365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New concepts in post-infarction ventricular remodeling.
    Udelson JE; Patten RD; Konstam MA
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function.
    Elsner D
    Eur Heart J; 1995 Dec; 16 Suppl N():52-8. PubMed ID: 8682062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurohumoral blockade in CHF management.
    Willenbrock R; Philipp S; Mitrovic V; Dietz R
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1 Suppl 1():24-30. PubMed ID: 11967792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.